Testing a new drug for men with rising prostate cancer markers
This study tests a new oral medication, deutenzalutamide, for men whose prostate cancer has come back after initial treatment (radiation or surgery) and whose PSA levels are doubling quickly. The drug works by blocking testosterone's effect on cancer cells, which may help slow or stop the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older.
- Your prostate cancer was treated with surgery or radiation (or both) in the past.
- Your PSA level has been rising, and the time it takes for your PSA to double is 9 months or less.
- Your testosterone level is above 150 ng/dL (meaning you have not had hormone therapy yet).
- You are generally healthy and able to take care of yourself (ECOG 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
This trial tests an experimental drug, GLR2037, for men with advanced prostate cancer that has spread to the bones or soft tissue and has progressed despite prior treatments. The drug may help slow the cancer's growth.
This trial tests a new drug combination (GZ17-6.02) for men with advanced prostate cancer that has stopped responding to standard hormone therapies. The goal is to see if the drug can help slow down the cancer.
This study tests a new drug called AZD6621 for men with metastatic prostate cancer that no longer responds to standard hormone therapy. The goal is to see how safe it is and whether it can slow down the cancer.
This trial tests a combination of enzalutamide (a hormone blocker) and an investigational antibody-drug (PDS01ADC) in men whose prostate cancer has come back after initial treatment, but has not yet spread extensively. It does not involve standard hormone therapy that lowers testosterone.
This trial tests a new oral drug, XNW5004, for men with advanced prostate cancer that has spread or stopped responding to standard treatments. It may be given alone or with other therapies like abiraterone, enzalutamide, or chemotherapy, and aims to find better ways to control the disease.
Hear when a new High Risk Biochemical Recurrence (BCR) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.